Bayer to buy Perfuse Therapeutics for $300M upfront
Bayer is committing $300 million upfront to buy ophthalmology biotech Perfuse Therapeutics and its mid-stage program targeting the leading causes of blindness. The deal appears to be Bayer’s first pharma M&A ...
ORIGINAL SOURCE →via Endpoint News
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · conflict
- [CONFLICT] Intermodal Asia
- [CONFLICT] UNDRR Regional Office for Arab States
- [CONFLICT] Digital security in war and conflict: challenges for civil society and tools for resilience
- [CONFLICT] Securing the Untrusted Agentic Development Layer
- [CONFLICT] Kuzey Kore'den dikkat çeken adım: 'Yeniden birleşme' ifadesi anayasadan çıkarıldı
- [CONFLICT] SON DAKİKA | Fenerbahçe başkan adayıydı! Barış Göktürk, Aziz Yıldırım'a desteğini açıkladı...